Menu Back toDA02: Current and Future Status of Post-Marketing Activities in Japan, the U.S., and Europe under the COVID-19 Pandemic

18th DIA Japan Annual Meeting 2021

All prices are exclusive of 10% Japanese consumption tax

DA02: Current and Future Status of Post-Marketing Activities in Japan, the U.S., and Europe under the COVID-19 Pandemic

Session Chair(s)

E. Stewart  Geary, MD

E. Stewart Geary, MD

  • Senior Vice President and CMO
  • Eisai Co., Ltd., Japan
Junko  Sato, PhD

Junko Sato, PhD

  • Director, Office of International Programs
  • Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Speaker(s)

Gerald J. Dal Pan, MD, MHS

Gerald J. Dal Pan, MD, MHS

  • Director, Office of Surveillance and Epidemiology, CDER
  • FDA, United States
Peter  Honig, MD, MPH, FACP

Peter Honig, MD, MPH, FACP

  • Senior Vice President Global Regulatory Affairs and Group Head Development China
  • Pfizer Inc, United States
Kiyohito  Nakai, PhD

Kiyohito Nakai, PhD

  • Director, Pharmaceutical Safty Division
  • Ministry of Health, Labour and Welfare (MHLW), Japan

Contact us